Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Free Cash Flow (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Free Cash Flow for 12 consecutive years, with -$197941.0 as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 198.2% to -$197941.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$515153.0, a 21.42% increase, with the full-year FY2025 number at -$383591.0, up 48.96% from a year prior.
  • Free Cash Flow was -$197941.0 for Q4 2025 at Regen BioPharma, down from -$160005.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$10463.0 in Q4 2022 to a low of -$1.1 million in Q3 2021.
  • A 5-year average of -$170781.3 and a median of -$118818.0 in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 96.25% in 2022, then tumbled 1451.52% in 2023.
  • Regen BioPharma's Free Cash Flow stood at -$279135.0 in 2021, then skyrocketed by 96.25% to -$10463.0 in 2022, then crashed by 1451.52% to -$162336.0 in 2023, then surged by 59.11% to -$66379.0 in 2024, then plummeted by 198.2% to -$197941.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Free Cash Flow are -$197941.0 (Q4 2025), -$160005.0 (Q3 2025), and -$55977.0 (Q2 2025).